To the Editor.
—Although we are well aware of the reported geographic and cultural differences that may influence the incidence of analgesic nephropathy, it remains difficult for us to explain and accept the sharp difference between the Georgetown University experience of Schreiner et al,1 with only 12 cases in ten years, and our local experience within a much smaller population area, of more than 35 cases in seven years.Furthermore, we believe Schreiner et al,1 Murray,2 and Gonwa et al3 are overlooking an important factor in considering the incidence of this disease in the population at large in comparison with that in the population with end-stage renal disease. Others have commented on the unusually high incidence of nonrenal deaths in this population,4 and this has certainly been our experience.Within the last five years, we are aware of seven patients with analgesic nephropathy who have died
Regester RF. Analgesic-Associated Nephropathy. Arch Intern Med. 1981;141(11):1556. doi:10.1001/archinte.1981.00340120164042